Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (17268)	1/25/2007 6:23:38 PM
From: bob zagorin	Read Replies (1) \| Respond to of 17367

a little more detail.. Novartis Drug Gets Approval In EU to Treat Eye Disease By a WALL STREET JOURNAL Staff Reporter January 25, 2007 Novartis AG's eye drug Lucentis received marketing approval in the European Union for the treatment of wet age-related macular degeneration, a leading cause of blindness in elderly people. Basel, Switzerland-based Novartis said Lucentis, which needs to be injected into the eyes, is the first drug that has been shown to improve vision in a significant number of people suffering from the disease. Currently available therapies, including Novartis's own drug Visudyne, only slow the decline in vision. Lucentis has been approved in Switzerland, India and the U.S.